Jazz Pharma Q2 2024: Sales Hit $513M

TL;DR

Jazz Pharma Q2 sales $513M, up slightly. Keep an eye on R&D.

AI Summary

Jazz Pharmaceuticals plc reported its financial results for the second quarter of 2024, ending June 30, 2024. The company's net product sales for the second quarter of 2024 were $513 million, a slight increase from the same period in the prior year. The filing also details various business segments and financial metrics relevant to the company's performance.

Why It Matters

This filing provides investors with a snapshot of Jazz Pharmaceuticals' financial health and operational performance for the second quarter of 2024, influencing investment decisions.

Risk Assessment

Risk Level: medium — The company operates in the highly regulated pharmaceutical industry, facing risks related to drug development, competition, and patent expirations.

Key Numbers

• $513M — Net Product Sales (Second quarter of 2024)

Key Players & Entities

• Jazz Pharmaceuticals plc (company) — Filer
• 20240630 (date) — Period of Report
• $513 million (dollar_amount) — Net Product Sales for Q2 2024

FAQ

Key Financial Figures

• $0.0001 — istered Ordinary shares, nominal value $0.0001 per share JAZZ The Nasdaq Stock Market

Filing Documents

• jazz-20240630.htm (10-Q) — 1623KB
• jazzq22024ex102.htm (EX-10.2) — 21KB
• jazzq22024ex311.htm (EX-31.1) — 10KB
• jazzq22024ex312.htm (EX-31.2) — 10KB
• jazzq22024ex321.htm (EX-32.1) — 7KB
• 0001232524-24-000068.txt ( ) — 8772KB
• jazz-20240630.xsd (EX-101.SCH) — 54KB
• jazz-20240630_cal.xml (EX-101.CAL) — 99KB
• jazz-20240630_def.xml (EX-101.DEF) — 302KB
• jazz-20240630_lab.xml (EX-101.LAB) — 708KB
• jazz-20240630_pre.xml (EX-101.PRE) — 511KB
• jazz-20240630_htm.xml (XML) — 1390KB

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements 3 Condensed Consolidated Balance Sheets – June 30, 2024 and December 31, 2023 3 Condensed Consolidated Statements of Income – Three and Six Months Ended June 30, 2024 and 2023 4 Condensed Consolidated Statements of Comprehensive Income – Three and Six Months Ended June 30, 2024 and 2023 5 Condensed Consolidated Statements of Shareholders' Equity – Three and Six Months Ended June 30, 2024 and 2023 6 Condensed Consolidated Statements of Cash Flows – Six Months Ended June 30, 2024 and 2023 8 Notes to Condensed Consolidated Financial Statements 9

Management's Discussion and Analysis of Financial Condition and Results of Operations

Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations 31

Quantitative and Qualitative Disclosures About Market Risk

Item 3. Quantitative and Qualitative Disclosures About Market Risk 48

Controls and Procedures

Item 4. Controls and Procedures 49

– OTHER INFORMATION

PART II – OTHER INFORMATION

Legal Proceedings

Item 1. Legal Proceedings 50

Risk Factors

Item 1A. Risk Factors 50

Unregistered Sales of Equity Securities and Use of Proceeds

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 50

Other Information

Item 5. Other Information 51

Exhibits

Item 6. Exhibits 52

SIGNATURES

SIGNATURES 53 We own or have rights to various copyrights, trademarks, and trade names used in our business in the U.S. and/or other countries, including the following: Jazz Pharmaceuticals , Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Xyrem (sodium oxybate) oral solution, Epidiolex (cannabidiol) oral solution, Epidyolex (the trade name in Europe and other countries outside the U.S. for Epidiolex), Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Enrylaze (the trade name in Europe and other countries outside the U.S. and Canada for Rylaze), Zepzelca (lurbinectedin), Defitelio (defibrotide sodium), Defitelio (defibrotide), Vyxeos (daunorubicin and cytarabine) liposome for injection, Vyxeos liposomal 44 mg/100 mg powder for concentrate for solution for infusion, CombiPlex and Sativex (nabiximols) oral solution. This Quarterly Report on Form 10-Q also includes trademarks, service marks and trade names of other companies. Trademarks, service marks and trade names appearing in this Quarterly Report on Form 10Q are the property of their respective owners. 2 Table of Contents

– FINANCIAL INFORMATION

PART I – FINANCIAL INFORMATION

Financial Statements

Item 1. Financial Statements JAZZ PHARMACEUTICALS PLC CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) (Unaudited) June 30, 2024 December 31, 2023 ASSETS Current assets: Cash and cash equivalents $ 1,355,802 $ 1,506,310 Investments 625,000 120,000 Accounts receivable, net of allowances 698,037 705,794 Inventories 542,555 597,039 Prepaid expenses 134,421 185,476 Other current assets 325,851 320,809 Total current assets 3,681,666 3,435,428 Property, plant and equipment, net 169,281 169,646 Operating lease assets 73,145 65,340 Intangible assets, net 5,079,462 5,418,039 Goodwill 1,735,931 1,753,130 Deferred tax assets, net 545,222 477,834 Deferred financing costs 5,736 6,478 Other non-current assets 71,425 67,464 Total assets $ 11,361,868 $ 11,393,359 LIABILITIES AND SHAREHOLDERS' EQUITY Current liabilities: Accounts payable $ 97,096 $ 102,750 Accrued liabilities 800,993 793,914 Current portion of long-term debt 605,798 604,954 Income taxes payable 52,138 35,074 Total current liabilities 1,556,025 1,536,692 Long-term debt, less current portion 5,100,983 5,107,988 Operating lease liabilities, less current portion 67,617 59,225 Deferred tax liabilities, net 775,228 847,706 Other non-current liabilities 99,416 104,751 Commitments and contingencies (Note 9) Shareholders' equity: Ordinary shares 6 6 Non-voting euro deferred shares 55 55 Capital redemption reserve 473 473 Additional paid-in capital 3,779,114 3,699,954 Accumulated other comprehensive loss ( 888,227 ) ( 842,147 ) Retained earnings 871,178 878,656 Total shareholders' equity 3,762,599 3,736,997 Total liabilities and shareholders' equity $ 11,361,868 $ 11,393,359 The accompanying notes are an integral part of these condensed consolidated financial statements. 3 Table of Contents JAZZ PHARMACEUTICALS PLC CONDENSED CONSOLIDATED STATEMENTS OF INCOME (In thousands, except per share amounts) (Unaudited) Three Months Ended June 30, Six Months Ended June 3

View Full Filing

View this 10-Q filing on SEC EDGAR